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1. Introduction 
Cancer is one of the world’s top killers accounting for 7.4 million deaths, or 13% of all deaths 
(World Health Organization [WHO], 2011). Colorectal cancer is the third most common and 
deadly cancer worldwide (Jemal et al., 2011). An unequal geographic distribution of the 
disease burden exists, with less developed areas of the world exhibiting the lowest incidence 
and mortality (Pitari et al., 2003). In contrast, populations dwelling in western countries are 
at increased risk to develop and die of colorectal cancer. In the US, 141,210 new cases are 
estimated to be diagnosed in 2011 and 49,380 patients are expected to die for this disease, 
representing an intolerable socio-economical toll (Siegel et al., 2011). 
Promises derive from substantial advancements in early detection and prevention strategies, 
which have contributed to reduce colorectal cancer incidence and mortality rates in recent 
years (Siegel et al., 2011). However, new chemotherapeutic approaches have not emerged 
and terminal clinical stages of the disease remain incurable. Specifically, invasion and 
metastatic disease progression, traditionally unnameable to surgical resection, are largely 
refractory to pharmacological therapy. About 90% of patients with distant metastasis die of 
the disease within 5 years from diagnosis (Siegel et al., 2011). Moreover, racial and 
educational health-disparities exist in which minorities and less educated individuals of the 
affected population exhibit the worst clinical prognosis and the highest mortality, in part 
reflecting their more advanced stages at diagnosis compared to other patient segments 
(Siegel et al., 2011). Together, these considerations underscore the enormous impact that 
therapeutic target discovery might have on western societies, especially if they would 
translate into innovative, curative pharmacological approaches that will prolong the 
survival of patients with colorectal cancer. 
Crucial systems regulating the intestinal crypt-villus axis are also important determinants of 
the carcinogenetic process (Aoki et al., 2003; Fodde et al., 2001; Korinek et al., 1998). Among 
these, the signalling pathway orchestrated by the surface receptor guanylyl cyclase C (GCC) 
has recently emerged as both an integral component of intestinal mucosa homeostasis and a 
negative regulator of the malignant cell phenotype. GCC, expressed in the epithelial layer of 
the gastrointestinal wall, and its endogenous ligands guanylin and uroguanylin control 
fluid balance and renewal crypt dynamics by operating sophisticated biochemical circuits in 
both the small and large intestine. Intriguingly, a bacterial mimicry of endogenous 
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hormones exists, the E. coli heat-stable enterotoxin (ST), which may confer both harmful 
(watery diarrhea) and beneficial (colorectal cancer resistance) effects to exposed individuals 
(Lucas et al., 2000; Pitari et al., 2001). In this model, the uneven epidemiological distribution 
of colon cancer incidence across different geographic areas of the world reflect, in part, 
inverse differences in the prevalence of enterotoxigenic E. coli infections (Pitari et al., 2003). 
Moreover, an unexplained mutation early in colorectal tumorigenesis leads to the loss of 
guanylin and uroguanylin expression, producing a dormant GCC pathway in neoplastic 











































Fig. 1. Significance of the dormant guanylyl cyclase C (GCC) pathway for colorectal 
carcinogenesis.  
Selected GCC signalling components with reported impact on tumorigenesis are depicted. 
A) In normal intestinal physiology, the GCC pathway is constitutively activated by 
paracrine hormonal regulation with the endogenous GCC agonists guanylin and 
uroguanylin. The active GCC pathway promotes signalling by proximal cGMP effectors 
cyclic nucleotide-gated channel (CNG), phosphodiesterases (PDE) and protein kinase G 
(PKG) that, in turn, affect the function of key distal effectors, including the v-akt murine 
thymoma viral oncogene homolog (AKT), Ca2+-sensing receptor (CaR), ┚-catenin, matrix 
metalloproteinase 9 (MMP-9), transforming growth factor ┚ (TGF-┚), and vasodilator-
stimulated phosphoprotein (VASP). As a result, tumorigenic forces are restrained and 
normal intestinal mucosa homeostasis is maintained. B) During neoplastic transformation 
the GCC pathway becomes dormant, principally because of the loss of endogenous hormone 
expression. Loss of signalling between GCC and the proximal cGMP effectors deregulates 
the distal components of the pathway, thereby producing an oncogenic system favouring 
colorectal cancer progression and metastasis. EMT, epithelial-mesenchymal transition. 
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This chapter will details the consequences at the functional and cellular level of the silenced 
GCC signalling for colorectal tumor formation and progression. Key molecular effectors 
comprising the GCC pathway with high clinical translational significance will be presented 
and their potential impacts for both diagnostic and therapeutic advances discussed. 
2. GCC and the intestinal crypt-villus axis 
GCC is a member of membrane-bound guanylyl cyclases (GCA to GCG), enzymes which 
catalyze the formation of cyclic guanosine monophosphate (cGMP) from GTP. Although 
they exhibit unique physicochemical and antigenic properties, particulate guanylyl cyclases 
are homodimeric transmembrane domain proteins sharing conserved cytoplasmic portions 
with tyrosine kinase-like and cyclase catalytic domains (Lucas et al., 2000). The amino acid 
sequence of GCC considerably diverges from the other isoforms in the extracellular domain, 
which represents the ligand binding domain for the E. coli heat-stable enterotoxin ST and 
the endogenous peptides guanylin and uroguanylin (Lucas et al., 2000). Beyond selected 
dopaminergic neurons in the central nervous system (Gong et al., 2011), in mammals GCC 
expression is principally restricted to brush-border membranes of epithelial cells lining the 
intestinal inner surface from the duodenum to the rectum, uniformly distributed along the 
crypt-villus axis (Lucas et al., 2000). This unique anatomical distribution subserves the 
functional role of GCC as a critical regulator of the intestinal mucosa homeostasis. In 
particular, the signalling pathway regulated by GCC and its second messenger cGMP 
contributes to the control of epithelial self-renewal and maturation dynamics underlying the 
integrity of the crypt-villus axis (Pitari et al., 2007). 
2.1 The GCC pathway 
Modulation of intracellular cGMP concentrations represents the fundamental event of a 
variety of signal transduction circuits shaping cellular behaviour. Synthesis (by guanylyl 
cyclases) and breakdown (by phosphodiesterases) are recognized as the major mechanisms 
defining cGMP levels in tissues. In intestinal epithelial cells, GCC is the principle source of 
cGMP (Lucas et al., 2000). GCC activity defines the type, intensity and duration of biological 
responses mediated by cGMP through unique physical, spatial and temporal dynamics at 
intestinal mucosal surfaces. The most important modality to regulate GCC activity is by 
ligand binding to its extracellular domain, which induces an intramolecular conformational 
change that is transmitted down to the cytoplasmic C-terminus catalytic domain. In this 
way, cellular cGMP levels can be raised numerous folds over basal states (Lucas et al., 2000; 
Schulz et al., 1989). Furthermore, the three ligand peptides know to induce GCC activation 
in mammalian cells exhibit different affinities and potencies for GCC, resulting in different 
patterns of cGMP concentrations/effects. The exogenous ligand ST, produced by E. coli and 
responsible for life-threatening diarrhoeagenic syndromes, is the most potent GCC agonist 
and consists of 18 amino acids with three intrachain disulfide bonds (Guarino et al., 1989). In 
contrast the endogenous paracrine hormones, guanylin and uroguanylin, are 15-16 amino 
acid long with two intrachain disulfide bonds and uneven tissue distributions and physico-
chemical characteristics. Thus, while uroguanylin is a more potent (~100 fold) and abundant 
GCC agonist at acidic pH of proximal intestinal tracts, guanylin is more potent (~4 fold) as a 
GCC agonist at basic pH and is highly expressed in the colon and rectum (Forte, 1999; 
Hamra et al., 1997). Finally, elegant spatio-temporal constrains along the crypt-villus axis 
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represent additional determinants of cGMP signalling by GCC. At the tissue level, maximal 
GCC activity and the dependant cGMP functions are imposed at the epithelial crypt/villus 
interface by increased GCC ligand expression (Cohen et al., 1995; Whitaker et al., 1997). In 
addition at the cellular level, compartmentalization of GCC-ligand interactions at luminal 
membrane borders establishes an increasing baso-apical cGMP gradient, wherein highest 
nucleotide concentrations are ensured at microvillus cell domains (Lucas et al., 2000). 
Beyond GCC activation, the functional consequences of cGMP rises in intestinal epithelial 
cells reflect the specific expression and compartmentalization of downstream target 
molecules. Two evolutionarily distinct allosteric binding sites for cGMP exist in eukaryotic 
cells: one is present in cGMP- (PKG) and cAMP- (PKA) dependent protein kinases and in 
the cyclic nucleotide gated (CNG) cation channels, while the other is expressed in cGMP-
regulated phoshodiesterases (PDEs). These proteins represent the intracellular receptors for 
cGMP and permit the selective transmission of information in a cell-(and subcellular-) 
specific manner. PKGs are Ser/Thr protein kinases comprising the soluble type I, widely 
distributed across tissues and including the isoforms I┙ and I┚, and the particulate type II, 
mainly expressed in the intestine (Pfeifer et al., 1999). PKA is a tetrameric kinase 
preferentially activated by cAMP (Chao et al., 1994). CNG channels are heterotetrameric 
proteins of ┙- and ┚-subunits, which mediate membrane Na+ and Ca2+ influx by cGMP in 
intestine as well as different other tissues (Bielet al., 1999). Further, cGMP-regulated PDEs 
(eg, PDE2, PDE5) are hydrolytic enzymes specialized in cleaving the cyclic nucleotide 
phosphodiester bond, thereby terminating correspondent biological activities (Corbin & 
Francis, 1999; Francis et al., 2011). Cyclic GMP binding to the consensus site of these 
intracellular targets results in regulation of important downstream effectors which control 
specific biochemical networks and cellular functions. Molecules distal to cGMP with 
paramount significance for intestinal cell biology include ions, ion channels, cytoskeleton 
regulators and enzymes. For instance, cGMP binding to two allosteric sites present at the 
amino-terminal region of PKG II fully activates the enzyme and induces phosphorylation 
and opening of the cystic fibrosis transmembrane conductance regulator (CFTR), a pivotal 
mechanism underlying control of intestinal fluid homeostasis (Pfeifer et al., 1999). For an in 
depth discussion on the regulation of the various biochemical cGMP-dependent targets, 
such as the CFTR channel, the reader is referred to other comprehensive reviews (Browning 
et al., 2010; Lucas et al., 2000; Steinbrecher & Cohen, 2011). Here, the focus will be on those 
molecular elements of the GCC and cGMP pathway that affect the epithelial cell phenotype, 
including its proliferative, morphogenetic and migratory attributes that greatly influence the 
crypt-villus homeostasis and the process of neoplastic transformation. 
2.2 Regulation of the intestinal epithelial cell phenotype 
The human intestinal mucosa is characterized by minute tubular invaginations called crypts, 
of maximal length in large intestinal tracts. In addition, the small intestinal mucosa exhibits 
lumenal protrusions of multi- (villi) and sub-cellular (microvilli) dimensions devoted to 
digestive activities. As a result, the inner intestinal surface is enormously expanded to 
optimally serve fundamental processes, from food processing and absorption to pathogen 
protection and immune system control (Montgomery et al., 1999). In this context, the 
complexity of those processes, constantly exposing the organism to potentially harmful 
external factors, is reflected by the sophisticated functional organization adopted by the 
columnar monolayer of epithelial cells lining the intestine. First, a self-renewal epithelial 
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ability is conferred by multipotent stem cells located at crypt bottoms, ensuring weekly 
cycles of cellular replacement to eliminate damaged or aging cells worn out by the 
demanding intestinal functions (Potten & Loeffler, 1990). Also, intriguing maturation 
dynamics are operating that turn proliferating progenitor cells into differentiated, cell cycle-
arrested epithelial cells with specialized functions, mostly populating the upper crypt and 
villus areas. They include a) the enterocytes, absorptive cells with food digestive functions 
(Montgomery et al., 1999), b) goblet cells, mucus-producing cells with detergent activities 
(Koldovsky et al., 1995), c) enteroendocrine cells, hormone-secreting cells comprising an 
intestinal endocrine system (Koldovsky et al., 1995), and d) Paneth cells, which secrete 
antimicrobial peptides and growth factors and are uniquely located at crypt bases (Bry et al., 
1994). Further, incompletely understood check-up mechanisms constantly detect genetic or 
epigenetic defects and direct epithelial cells to the appropriate maintenance (e.g., cell 
resistance), self-repair (e.g., DNA excision repair) or death (e.g., apoptosis, autophagy) 
program (Potten & Loeffler, 1990). Finally, the spatio-temporal coordination of this variety 
of processes is ensured by the migratory nature of the epithelial monolayer that physically 
maps the proliferation-differentiation transition at crypt/villus (small intestine) or 
lower/upper crypt (colon) interfaces, and drives the shedding of senescent cells at mucosal 
tips (Montgomery et al., 1999). 
The GCC signalling pathway represents one of the elaborate homeostatic mechanisms 
evolved to direct the integration of each component supporting the intestinal epithelial cell 
phenotype. Indeed, targeted deletion of guanylin expression induces expansion of the 
proliferating crypt compartment and accelerated cell migration in mouse colon, presumably 
as a consequence of reduced GCC activation and cGMP-dependent signalling (Steinbrecher 
et al., 2002). In agreement with this notion, elimination of GCC in mice produces 
hyperplastic colonic crypts, populated by a higher number of fast-cycling and fast-migrating 
progenitor cells, associated with impaired cell maturation and death dynamics, with fewer 
Paneth and goblet cells but increased apoptotic events (Li et al., 2007a). Moreover, 
compound mice in which the expression of uroguanylin or GCC has been disrupted exhibit 
similar structural alterations in the crypt-villus axis, with loss of tight junction-mediated 
intestinal barrier function and increased mucosal permeability (Han et al., 2011). Of 
relevance, intestine-specific expression of GCC is under the control of the caudal homeobox 
gene Cdx2, a transcriptional factor regulating development and cell fate specification of 
intestinal epithelial cells (Park et al., 2000). The Cdx2 gene product binds a consensus site 
present in the GCC proximal promoter and stimulates GCC transcription in an intestine-
specific fashion (Di Guglielmo et al., 2001). Thus, it is tempted to speculate that GCC 
expression and the dependant cGMP signalling are part of the universal developmental 
program supporting the integrity of the intestinal crypt-villus axis. 
Molecular mechanisms underlying effects of the GCC pathway on the intestinal cell 
phenotype have only recently been investigated. In one paradigm, lumenal Ca2+ is the key 
distal mediator of GCC activity (Pitari et al., 2003, 2008). The role of dietary Ca2+ as 
antiproliferative agent and promoter of differentiation and cell death along the epithelial 
crypt-villus axis is well defined (Lipkin & Newmark, 1995; Whitfield, 1992), and Ca2+-
deficient diets induce larger proliferative compartments in mouse colonic crypts (Rozen et 
al., 1989). One key molecular target for antiproliferative effects by dietary Ca2+ is the Ca2+-
sensing receptor (CaR), a G protein-coupled receptor present at apical membranes of 
intestinal epithelial cells (Sheinin et al., 2000). Binding of Ca2+ to the N-terminal extracellular 
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domain of CaR initiates discreet intracellular events mediated by the second messengers 
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), which result in mobilization of 
intracellular Ca2+ and protein kinase C (PKC) activation, respectively (Berridge et al., 2000; 
Gama et al., 1997; Rhee, 2001). Intriguingly, elimination of GCC expression in mice is 
associated with loss of CaR from enterocyte brush borders (Pitari et al., 2008). Moreover, 
expression of CaR and GCC ligands is maximal at upper-crypt areas (Chakrabarty et al., 
2005; Cohen et al., 1995; Whitaker et al., 1997), where epithelial cells stop proliferation and 
enter the maturation program, suggesting that CaR activity may be subordinated to GCC 
signalling along the crypt–villus axis (Pitari et al., 2008). Further, lumenal Ca2+ (1-3 mM) 
triggering cell cycle arrest at colonic mid-crypts (Whitfield et al., 1995) opposes pro-
proliferative ┚–catenin activity and favour p21- and p27-mediated differentiation 
(Chakrabarty et al., 2003, 2005), molecular effectors also regulated by cGMP signalling in the 
intestine (Lin et al., 2010; Liu et al., 2001). Thus, GCC signalling may promote the 
proliferation-differentiation transition of intestinal epithelial cells through CaR regulation 
(Pitari et al., 2008). This is important as CaR is also the receptor for other polyvalent cations 
(i.e., Gd3+, Mg2+, Ni2+) and polyamines (i.e., spermine, spermidine, putrescine) produced by 
commensal colonic bacteria (Hofer & Brown, 2003), pointing to a crucial role of the GCC-
CaR pathway as regulator of a variety of antiproliferative signals in intestine (Pitari et al., 
2008). In addition, lumenal Ca2+ may mediate intestinal GCC actions through CaR-
independent mechanisms, including ionic currents by CNG channels (Biel et al., 1999; Pitari 
et al., 2003, 2008). Cyclic GMP-gated Ca2+ current through CNG is a major regulator of 
signal generation and transmission in excitable cells (Ames et al., 1999; Zufall et al., 1997). Of 
relevance, in colon cancer cells GCC signalling slows cell cycle progression, in part, by 
inducing cGMP-dependent CNG channel activation, intracellular Ca2+ influx and cytosolic 
Ca2+ rises (Pitari et al., 2003). 
Another model proposes the v-akt murine thymoma viral oncogene homolog (AKT) as the 
master biological effector of the GCC pathway (Lin et al., 2010). AKT regulates survival 
and metabolic circuits in proliferating intestinal cells, and AKT over activation promotes 
crypt hyperplasia and tumorigenesis in mouse intestine (Sakatani et al., 2005). 
Importantly, elimination of GCC expression in mice results in hyperactivation of AKT 
signalling pathways, associated with expanded crypt compartments populated by 
glycolytic cells with accelerated G1-S cell cycle transition (Lin et al., 2010). Conversely, loss 
of GCC and cGMP signalling restricts the differentiated villus compartment and 
diminishes mitochondria-dependent oxidative metabolism in intestinal epithelial cells 
(Lin et al., 2010). Investigations employing genetic and pharmacologic manipulation of 
AKT confirmed that GCC signalling through cGMP control the proliferative cell 
metabolism by decreasing the function of AKT (Lin et al., 2010). Thus, AKT-dependent 
regulation of cell survival and glycolytic metabolism along the crypt-villus axis, at the 
basis of intestinal mucosa development and homeostasis, may be conditionally regulated 
by the activity of the GCC pathway, whose increasing crypt-villus gradient directly 
correlates with differentiation and oxidative phosphorylation. 
2.3 Regulation of epithelium-stroma interactions 
Beyond the epithelium, the intestinal wall also encompasses mesenchymal and a smooth 
muscle layers. The intestinal mesenchymal compartment comprises mucosal and 
submucosal layers of connective tissues, composed of both acellular (e.g., glycoproteins, 
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hyaluronic acid, proteoglycans, collagen I and III) and cellular components (e.g., fibroblasts, 
myofibroblasts, leukocytes, endothelial cells). The basement membrane, a balanced mix of 
matrix components (e.g., nidogen, laminin, collagen IV, perlecan), physically separates the 
enterocytes from the underlying mesenchyme. The basement membrane and all the other 
mesenchymal components significantly contribute to the dynamic renewal of intestinal 
epithelial cells. Indeed, intestinal epithelium-stroma interactions contribute to maintain the 
crypt-villus homeostasis through direct cell-matrix and cell-cell contacts or paracrine 
signalling (Montgomery et al., 1999; Pinchuk et al., 2010). In contrast, corrupted epithelium-
stroma interactions promote the initiation and progression of an array of intestinal 
pathologies (Kraus & Arber, 2009; Suzuki et al., 2011). 
Studies with targeted deletion of GCC in mice revealed striking morphogenetic alterations 
affecting the extra-epithelial layers of the intestine (Gibbons et al., 2009). Indeed, the 
intestinal wall of these mice is significantly enlarged compared to mice with normal GCC 
expression. The mesenchymal compartment exhibits hypertrophy as a result of both 
exaggerated activation of its cellular elements and increased deposition of its interstitial 
matrix components (Gibbons et al., 2009). In particular, an increased ratio of activated 
myofibroblasts over quiescent fibroblasts is present in mice with loss of GCC signalling, an 
alteration which contributes to the establishment of a reactive stromal environment 
characterized by overexpression of collagen I, tenascin C and matrix metalloproteinase 9 
(MMP-9) (Gibbons et al., 2009). In part, these alterations appear to be the consequence of an 
increased interstitial activity of the profibrinogenic transforming growth factor ┚ (TGF-┚), as 
GCC signalling through cGMP inhibits TGF-┚ secretion and function in intestinal epithelial 
cells and opposes stromal remodelling underlying inflammatory processes (Gibbons et al., 
2009). Further, intestinal smooth muscle layers of mice lacking GCC signalling exhibit 
hyperplasia and hypertrophy, which represent important contributors of the transmural gut 
enlargement in these animals (Gibbons et al., 2009). Thus, the GCC pathway operating in 
intestinal mucosal cells exerts strong developmental and functional influences on the 
underlying stroma, presumably by regulating discreet hormonal circuits supporting 
epithelial-mesenchymal crosstalk (Pitari et al., 2007). Given the established role of the 
intestinal mesenchyme in inflammation and tumorigenesis (Kraus & Arber, 2009; Pinchuk et 
al., 2010; Suzuki et al., 2011), it is possible to speculate that dysregulation of GCC signalling 
in intestinal epithelial cells may favour the emergence of a reactive stromal environment 
promoting pathological processes. 
3. GCC and intestinal transformation 
Colorectal carcinogenesis comprises a pathological continuum turning pre-cancerous lesions 
into invasive malignant tumors. The process begins with single (epi)genetic mutations 
driven by carcinogenic insults that disrupt the physiological epithelial cell phenotype (Gryfe 
et al., 1997; van Engeland et al., 2011). As a result, the balance of migration, proliferation, 
differentiation and cell death along the colonic crypt-surface axis is perturbed and 
neoplastic cells with limitless replicative potential emerge. Remodelling of the surrounding 
stroma also participates to the promotion and progression of transformation, imposing cell 
non-autonomous drivers of tumorigenesis such us angiogenesis and inflammation (Kraus & 
Arber, 2009; Suzuki et al., 2011). Ultimately, malignant cells lose their epithelial 
characteristics and acquire a mesenchymal phenotype that enables them to translocate and 
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establish new colonies at distant sites, such as the liver, lung and peritoneum (Nicolson, 
1988; Polyak & Weinberg 2009; Suzuki et al., 2011). 
The paracrine hormone hypothesis of colorectal cancer suggests that sporadic intestinal 
tumorigenesis is a process initiated by loss of endogenous GCC ligand expression, which 
induces a state of guanylinopenia and uroguanylinopenia (Pitari et al., 2007). Indeed, 
extensive studies have demonstrate that early in transformation intestinal epithelial cells 
acquire a mysterious mutation that renders pre-cancerous adenomatous lesions devoid of 
guanylin and uroguanylin (Birkenkamp-Demtroder et al., 2002; Cohen et al., 1998; 
Notterman et al., 2001; Steinbrecher et al., 2000). Those reports suggest that guanylin and 
uroguanylin, organized in a tail-to-tail configuration on human chromosome 1p, are the 
most commonly lost gene products in colorectal cancer in both animals and humans, 
exhibiting mutational frequency rates comparable to that of APC. Conversely, GCC is 
retained in colorectal cancer cells, which often exhibit higher GCC expression levels 
compared to normal epithelial tissues (Schulz et al., 2006; Witek et al., 2005). Increased GCC 
in the context of reduced guanylin and uroguanylin expression probably reflects the 
common pharmacological paradigm of receptor upregulation following specific ligand 
deprivation. More importantly, dysregulation of GCC signalling with an intact, but silent 
(for failure of ligand-dependent activation), intracellular molecular pathway produces a 
dormant cGMP-regulated system, which might be pathognomonically associated with 
neoplastic disease progression (Pitari et al., 2007). In this model, colorectal carcinogenesis 
following paracrine GCC ligand insufficiency reflects the central role of GCC in 
coordinating processes maintaining epithelial cell homeostasis and the crypt-villus axis, 
including the proliferation-differentiation balance, migration, metabolic programming and 
mesenchymal development (Li et al., 2007a; Pitari et al., 2007). 
3.1 Regulation of the colon cancer cell phenotype 
Neoplastic cell transformation ensues from the stepwise accumulation of mutations that 
produce hyper functioning oncogenes and silenced tumor suppressors (Bishop & 
Weinberg, 1996). Universally, the final combination of all the mutations and signalling 
deregulations occurring in cancers has similar functional consequences, the promotion of 
tumor cell growth and dissemination, and the evasion of host mechanisms of elimination 
(e.g., immuno-surveillance) (Hanahan & Weinberg, 2000). In intestinal tumorigenesis, 
acquisition of these malignant traits resembles a pathological amplification of the crypt 
stem cell phenotype, which self-perpetuates through relentless rounds of cell proliferation 
and migration (Montgomery et al., 1999; Potten & Loeffler, 1990). Conversely, invasive 
cancer cells progressively lose the morphology and metabolism of the differentiated 
epithelium, acquiring the ancestral functional plasticity of pluripotent stem cells. Indeed, 
overexpression of molecules (Wnt, ┚-catenin, Tcf) that support the crypt cell compartment 
(Gregorieff & Clevers, 2005; Korinek et al., 1998), or disruption of gene products (the 
adenomatous polyposis coli gene APC, Smad, CDX-2) restricting it (Aoki et al., 2003; 
Fodde et al., 2001; Tang et al., 2005) promotes intestinal tumorigenesis in animal models. 
In close agreement with these observations, the majority of sporadic human colorectal 
cancers exhibits a perturbed APC signalling as the initial mutational event, which 
crystallizes crypt-like nuclear proliferative programs driven by the ┚-catenin/Tcf complex 
(Fodde et al., 2001). 
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Since it regulates crypt compartments and the proliferation-differentiation balance along the 
crypt-villus axis (Li et al., 2007a; Pitari et al., 2007), dormancy of the GCC signalling 
pathway contributes to neoplastic transformation in the intestine (Li et al., 2007a; Pitari et 
al., 2007). Indeed, the increased migration and proliferation induced by loss of GCC 
signalling in mucosal colonocytes (Li et al., 2007a) represents a significant oncogenic stress 
(Aoki et al., 2003; Spruck et al., 1999) that creates the pre-neoplastic intestinal crypt (Pitari et 
al., 2007). Accordingly, cell cycle progression and growth of human colon cancer cells, 
experimental mimicry of the GCC dormancy characterizing the human disease because they 
express GCC but not the endogenous ligands (Lucas et al., 2000; Pitari et al., 2001), are 
greatly impaired upon reactivation of GCC signalling with exogenous supplementation of 
its specific agonists (Pitari et al., 2001, 2003, 2005, 2008). Ligand-dependent GCC activation 
restores lost cGMP-regulated circuits and imposes cancer cytostasis by reducing nuclear 
DNA synthesis and the G1/S transition (Lin et al., 2010; Pitari et al., 2001). Antiproliferation 
by GCC, in part, is mediated by extracellular Ca2+ actions at cancer cell membrane surfaces, 
through its dependant effects on CaR activation and CNG channel-mediated Ca2+ influx 
(Pitari et al., 2003; Pitari et al., 2008). In addition, reactivation of GCC signalling through 
cGMP opposes the Wnt/┚-catenin/Tcf4 signalling axis, the regulator of the proliferative 
crypt phenotype and tumor promoter in intestine (Pinto & Clevers 2005; Reya & Clevers 
2005; van Es et al., 2005), by directly inhibiting ┚-catenin stability (Liu et al., 2001; Thompson 
et al., 2000). Underscoring the significance of the dormant GCC pathway in colon cancer, 
elimination of GCC in mice significantly enhances intestinal tumor initiation and 
progression (Li et al., 2007b). Mice deficient of GCC signalling exhibit enhanced sensitivity 
to tumorigenesis induced by ApcMin/+ and the carcinogen azoxymethane, reflected by 
increased tumor incidence, multiplicity, and burden (Li et al., 2007b). A principal 
mechanism by which GCC promotes colorectal tumorigenesis is the perturbation of 
regulators of G1/S cell cycle transition, including increased expression of oncogenes cyclin 
D1 and pRb, and decreased activity of tumor suppressor p27 (Li et al., 2007b). Beyond 
hyperproliferation, GCC-deficient mice also exhibit increased genomic instability in their 
intestinal mucosa cells. In particular, an increased incidence of DNA breaks, loss of 
heterozygosity and point mutations in genes central to tumorigenesis, including APC and ┚-
catenin, are observed along the crypt-villus axis (Li et al., 2007b). Although it remains 
unclear, the molecular mechanism mediating maintenance of the genome by GCC, including 
damage detection or mutational repair, appears to be distinct from that regulating 
proliferation (Li et al., 2007b). Rather, proliferative restriction and genomic quality control 
reflect two reinforcing systems by which the GCC pathway opposes intestinal 
carcinogenesis (Li et al., 2007b; Pitari et al., 2007). While accelerated G1/S cell cycle 
transition favours inheritance and amplification of genetic mutations (Aoki et al., 2003; 
Spruck et al., 1999), instability involving tumor suppressors or oncogenes further 
deregulates the cancer cell cycle (Spruck et al., 1999). 
Another consequence of a dormant GCC pathway in colorectal transformation is the 
promotion of the cancer cell metabolism (Lin et al., 2010). As discussed above, intestinal 
crypt stem cells principally rely on glycolysis to produce ATP and support their metabolism. 
Activation of GCC signalling restricts the glycolytic crypt compartment and favours the 
acquisition of mitochondria-mediated oxidative phosphorylation by differentiated epithelial 
cells in villi (Lin et al., 2010). Importantly, neoplastic cells utilize glycolytic ATP as their 
source of energy, even in the context of optimal environmental oxygen levels (Capuano et 
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al., 1997; Kroemer, 2006; Pelicano et al., 2006). Dr. Otto Warburg first described this 
malignant paradox suggesting that cancer cells undergo metabolic reprogramming, wherein 
they switch from oxidative phosphorylation to aerobic glycolysis to produce ATP (Warburg, 
1956). This malignant transition provides a competitive advantage to cancer cells that have a 
readily accessible supply of energy and substrates to support proliferation, adapt to the 
hypoxic tumor microenvironment, and promote invasion. Of relevance, restoration of GCC 
signalling by exogenous ligand administration increases the number, size and function of 
mitochondria in human colon cancer cells (Lin et al., 2010). Tumor reversion to 
mitochondria-dependent oxidative metabolism is associated with concurrent reduction in 
rate-limiting glycolytic enzymes, and reflects modulation of AKT and its downstream 
effectors (e.g., mTOR) by GCC signalling reactivation (Lin et al., 2010). Thus, while GCC 
signalling in human colon cancer cells induces expression of critical transcription factors 
required for mitochondrial biogenesis (PGC1┙, mtTFA, NRF1), inhibition of glycolysis by 
GCC results in a reduced ability of tumors to uptake glucose and produce lactate (Lin et al., 
2010). Importantly, elimination of AKT rescues the tumorigenic intestinal phenotype of mice 
deficient in GCC signalling (Lin et al., 2010), underscoring the central role of metabolic 
circuits in mediating inhibition of colorectal carcinogenesis by GCC. Together, these 
observations suggest that the dormant GCC pathway, produced by hormone deprivation 
early in transformation (Birkenkamp-Demtroder et al., 2002; Cohen et al., 1998; Notterman 
et al., 2001; Steinbrecher et al., 2000), can be envisioned as a loss-of-function mutation of a 
tumor suppressor system, which promotes crypt stem-like proliferation and metabolism and 
favours genomic instability and the development of the colon cancer cell phenotype. 
3.2 Regulation of the colon tumor microenvironment 
The tumor microenvironment is recognized as a major determinant of cancer formation, 
growth and dissemination (Fidler, 2001; Kraus & Arber, 2009; Suzuki et al., 2011). Both 
cellular and acellular components comprising the tumor stroma contribute to intestinal 
transformation, reflecting the intimate crosstalk between tumor epithelial cells and the 
underneath mesenchyme (Kraus & Arber, 2009; Suzuki et al., 2011; Witz & Levy-
Nissenbaum, 2006). Thus, interstitial matrix remodelling, secretion of paracrine factors by 
stromal cells, lymphocyte-mediated immunoresponses, and neo-angiogenesis significantly 
influence cancer development (Fidler, 2001; Kraus & Arber, 2009; Suzuki et al., 2011). 
Among the molecular mediators of cancer-mesenchyme interactions, the matrix 
metalloproteinases (MMPs) play an essential role (Zucker & Vacirca, 2004). MMPs are a 
family of zinc-dependent metalloendopeptidases that cleave interstitial matrix components, 
growth factors, chemokines and cell surface receptors creating a nurturing niche for cancer 
growth and invasion (Cox & O'Byrne, 2001; Curran & Murray, 2000; McCawley & Matrisian, 
2001). Depending on their substrate specificities, MMPs are divided into collagenases, 
gelatinases, stromelysins, and matrilysins (Stamenkovic, 2003). 
The soluble collagenase MMP-9 has been conclusively linked with colorectal carcinogenesis 
(Chu et al., 2011; Lubbe et al., 2006; Nascimento et al., 2010; Zucker & Vacirca 2004; Zuzga et 
al., 2008). Structurally, MMP-9 (92-kDa protein) consists of a pro-peptide sequence, a 
catalytic domain containing the zinc binding site and fibronectin type II-like repeats, which 
promote MMP-9 binding to gelatin and elastin (Fridman et al., 2003; Shipley et al., 1996). 
Although enzymatic-independent signalling also has been reported (Bjorklund et al., 2004; 
Librach et al., 1991), the catalytic activity of MMP-9 is the principal mediator of tumor 
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matrix remodelling (Fridman et al., 2003; Lubbe et al., 2006). In this way, MMP-9 degrades 
basement membrane collagen type IV, allowing intestinal tumor epithelial cells to invade 
the adjacent stromal compartment (Fridman et al., 2003). Moreover, MMP-9 promotes tumor 
angiogenesis by specifically processing and releasing TGF-┚ and VEGF from cancer cell 
surfaces and the interstitial matrix, respectively (Bergers et al., 2000; Qian et al., 1997; Yu & 
Stamenkovic, 2000). Given its crucial role in those pathological processes, MMP-9-
dependent proteolytic activity is considered a driving force conferring the migratory and 
invasive phenotype to cancer cells and favouring tumor progression (Bergers et al., 2000; 
Fridman et al., 2003; Lubbe et al., 2006; Yu & Stamenkovic, 2000). Consequently, MMP-9 
activity needs to be tightly controlled in biological tissues. Indeed, normally MMP-9 is a 
silent protease, secreted by cancer cells as a pro-zymogen that is activated only upon 
cleavage of its 10-kDa N-terminal pro-peptide by various proteases (e.g., MMP-2, MMP-3, 
MMP-13, plasmin, thrombin) (Ahmed et al., 2003; Fridman et al., 2003; Ramos-DeSimone et 
al., 1999). Endogenous inhibitors of MMP-9 also exists (e.g., the tissue inhibitor of matrix 
metalloproteinase 1) which bind to both the pro- and the active-form of MMP-9 and 
neutralize its proteolytic activity (Goldberg et al., 1992; Stamenkovic, 2003). 
Beyond inhibition of catalytic activity, regulation of zymogen expression and secretion 
represents additional effective modalities to contain tumorigenic MMP-9 functions (St-Pierre 
et al., 2003; Zhang et al., 2006). Cyclic GMP inhibits the synthesis and secretion of MMP-9 in 
various cell systems (Akool el et al., 2003; Gurjar et al., 1999). Accordingly, restoration of 
ligand-dependent GCC signalling though cGMP induces a compartmental redistribution of 
colon cancer cell MMP-9, in which intracellular retention results in reciprocal extracellular 
depletion of that collagenase (Lubbe et al., 2009). As a consequence, MMP-9 proteolytic 
activities at the pericellular tumor space are suppressed, with abrogation of MMP-9-
dependent interstitial matrix remodelling and cell spreading (Lubbe et al., 2009). 
Conversely, mutational dormancy of the GCC pathway early in transformation 
(Birkenkamp-Demtroder et al., 2002; Cohen et al. 1998; Notterman et al., 2001; Steinbrecher 
et al., 2000) may permit the emergence of a pro-tumorigenic stromal environment 
characterized by increased MMP-9 secretion, break-down of epithelial basement membranes 
by MMP-9 catalytic activity and disruption of homeostatic epithelial-mesenchymal 
interactions. It has been proposed that GCC effect on spatiotemporal MMP-9 dynamics in 
colon cancer cells has a profound impact on the overall tumor phenotype, because by 
disrupting its surface localization, membrane anchoring and focal catalytic activity it 
suppresses oncogenic MMP-9 functions (Lubbe et al., 2009). 
4. GCC and colorectal cancer metastasis 
Cancer metastasis consists in the dissemination of tumor cells to distant locations (Fidler, 
2003). Clinically, metastasis coincides with the most terminal disease stages, incurable 
conditions associated with poor prognosis and survival (Mehlen & Puisieux, 2006; Siegel et 
al., 2011). Pathogenetically, it comprises a sequence of distinct, individual processes 
including cancer cell invasion of the primary site, intravasation and distribution through 
blood or lymphatic vessels, and colonization of target organs (Fidler, 2003; Folkman, 1986; 
Nicolson, 1988). Following organ seeding, tumor cells have to migrate into and invade tissue 
parenchyma (Wanget al., 2004; Steeg, 2006), resist to local immune defences and establish a 
nurturing micro-environment to develop and growth (Fidler, 2003; Folkman, 1986). In colon 
cancer, preferred organs of metastatic colonization include the liver, lung and peritoneum. 
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Once colorectal cancer has spread to these organs, the risk of mortality increases 
dramatically, and ~90% of patients diagnosed with distant metastasis die within 5 years 
from diagnosis (Siegel et al., 2011). Indeed, the management of patients with colorectal 
cancer metastasis is characterized by the highest incidence of therapeutic failure, in which 
surgery is not practicable (Pihlet al., 1981; Shapiro, 1992) and adjuvant chemotherapy is 
ineffective (increasing median survival only few months) (Meyerhardt & Mayer, 2005). 
The functional phenotype of metastatic cells is unique and very selective. It has been 
calculated that of intravasated tumor cells, only a minute fraction remains viable after 24 
hour, and >99.99% are eliminated before reaching their target organ (Fidler, 1970). This 
metastatic inefficiency reflects the scarcity of cancer cell clones exhibiting the full molecular 
machinery to execute all the individual steps comprising the metastatic process (Fidler, 1970; 
Weiss, 1990). In that context, since its inception primary colorectal cancer consists of 
biologically heterogeneous cell subpopulations, among which are present those possessing 
the ability to migrate and spread to distant parenchyma (Fidler, 2003; Heppner, 1984). 
Intriguingly as demonstrated by extensive immune detection and mRNA analyses of clinical 
specimens, GCC is uniformly expressed in metastatic colon tumors regardless of anatomical 
location (Carrithers et al., 1994; Carrithers et al., 1996; Waldman et al., 1998). Moreover, the 
structural and functional integrity of GCC and its principal downstream effectors appears to 
be preserved in metastasis, as colorectal cancer cells at extra-intestinal sites exhibit identical 
binding characteristics to, and signalling activation by, the exogenous ligand ST to those of 
normal intestinal cells (Carrithers et al., 1994; Schulz et al., 2006; Witek et al., 2005). However 
away from its primary organ, GCC is a ligand-starved receptor with an intracellular 
dormant pathway, as normal mucosal cells in intestine are the principal producers of 
endogenous hormones guanylin and uroguanylin (Forte, 1999). Thus, the loss of GCC ligand 
expression early in transformation (Birkenkamp-Demtroder et al., 2002; Cohen et al., 1998; 
Notterman et al., 2001; Steinbrecher et al., 2000) may be part of the exclusive phenotypic 
mutations conferring a pro-metastatic evolutionary advantage to selected colon cancer 
clones (Lubbe et al., 2009; Pitari et al., 2007; Zuzga et al., 2011). 
4.1 Control of invasive cell shape 
To successfully execute the metastatic program, transformed cells require a dynamic actin 
cytoskeleton. Thus, a hallmark of metastasis is the abandon of the static epithelial cell 
polarity and the acquisition of plastic membrane borders with specialized actin-based 
organelles promoting locomotion and invasion (Fidler, 2003; Steeg, 2006). Similarly to 
lymphocytes or neutrophils at inflammatory sites, cancer cells constantly remodel their actin 
to assume atypical morphological architectures, a process often referred to as epithelial-
mesenchymal transition (Polyak & Weinberg, 2009). Changes in cell shapes reflect profound 
molecular rearrangements at tumor surfaces, including loss of E-cadherin-dependent cell-
cell contacts and transient assembly of integrin-driven cell-matrix adhesions (Avizienyte et 
al., 2004, 2005; Polyak & Weinberg, 2009). These processes permit de novo development of 
membrane protrusions, such as filopodia and lamellipodia for probing the matrix during 
spreading and migration, and invadopodia for focal proteolytic matrix degradation in 
invasion (Linder, 2007; Yamaguchi & Condeelis, 2007). 
In general, common molecular regulators coordinate tumor cytoskeletal remodelling by 
transducing external signals into actin processes. In colon cancer cells, tyrosine kinase 
receptors (e.g., EGF receptor, Eph receptors, Met receptors), G protein-coupled receptors 
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(e.g., cholecystokinin receptors) and cytokine receptors (e.g., chemokine receptors, TGF-┚ 
receptor) have been established as important inducers of the metastatic cell morphology 
(Dienstmann & Tabernero 2010; Dong et al., 2009; Fulton, 2009; Kitamura et al., 2010; Larsen 
& Dashwood, 2010; Ongchin et al., 2009; Yuet al., 2006). They activate the intracellular 
signalling system controlling cytoskeletal actin (e.g., focal adhesion kinases, rho-GTPases, 
Arp2/3 complex), which assembles the membrane protrusive structures mediating invasion 
(Linder, 2007; Yamaguchi & Condeelis, 2007). Normally restricted at intestinal epithelial 
brush borders (Lucas et al., 2000), GCC is ideally positioned to affect those molecular 
networks and exert spatio-temporal control of actin remodelling. Indeed, ligand-dependent 
GCC signalling through cGMP appears to act as a suppressor of metastatic cell morphology 
in intestine (Lubbe et al., 2009; Zuzga et al., 2011). Thus, colon cancer cells assume a rounded 
shape upon GCC signalling activation, with elimination of F-actin rich filopodia and 
lamellipodia (Lubbe et al., 2009). The number and length of cancer cell invadopodia also 
significantly decreases after activation of the GCC pathway (Zuzga et al., 2011). Importantly, 
failure to form protrusive structures forces tumor cells to aggregate into compact colonies 
devoid of spreading and invading abilities (Lubbe et al., 2009; Zuzga et al., 2011). Together, 
these observations suggest that the GCC pathway is one of the intrinsic homeostatic systems 
that maintain the stable epithelial cell polarity, shape and tight junctions, which form the 
essential mucosal barrier between the intestine and the external environment (Han et al., 
2011). This notion is further supported by the inhibitory role that GCC signalling exerts on 
known inducers of epithelial-mesenchymal transition (Polyak & Weinberg, 2009), including 
the reactive stromal environment (with enhanced TGF-┚ and MMP-9 activities) (Gibbons et 
al., 2009) and the stem cell-promoting PI3K/AKT system (Lin et al., 2010). Hence, 
dysregulation of GCC signalling in intestinal tumorigenesis may enable the epithelial-
mesenchymal transition required for cancer cell dissemination (Lubbe et al., 2009). 
A key intracellular effector of the GCC pathway that regulates colon cancer cell shape is the 
vasodilator-stimulated phosphoprotein (VASP) (Zuzga et al., 2011). Ena/VASP family 
proteins control F-actin geometry supporting cell motility (Krause et al., 2003). VASP 
promotes filopodia and lamellipodia formation and extension by organizing molecular 
complexes comprising G-actin, F-actin and actin regulatory proteins (Krause et al., 2003). It 
functions by protecting actin barbed ends from binding to capping proteins, thereby 
permitting filament elongation (Bear et al., 2002; Mejillano et al., 2004). Three critical 
domains enable VASP to intimately interact with the actin cytoskeleton (Krause et al., 2003), 
including 1) the N-terminus Ena/VASP homology 1 (EVH1), which binds to focal adhesion 
proteins vinculin and zyxin, 2) the central prolin-rich region, which contains a consensus 
binding motif for the G-actin-binding protein profilin, and 3) the C-terminus EVH2, which 
binds to both G- and F-actin and mediates VASP oligomerization. Importantly, Ser239 
within the EVH2 VASP domain is a preferred phosphorylation site for PKG, functioning as a 
biological marker for cGMP signalling in intestinal (Deguchi et al., 2002) and other cells 
(Krause et al., 2003; Yaroslavskiy et al., 2005). Cyclic GMP-dependent VASP 
phosphorylation inhibits membrane protrusion formation in normal cells (Krause et al., 
2003; Lindsay et al., 2007). Accordingly, in colorectal cancer cells VASP Ser239 
phosphorylation induced by ligand activation of GCC signalling through cGMP and PKG 
induces rapid disassembly (less than 10 minutes) of invasive and migratory membrane 
organelles (Zuzga et al., 2011). Herein, GCC promotes VASP removal from tumor 
membrane protrusions with subsequent collapse of the F-actin infrastructure supporting 
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filopodia and invadopodia (Zuzga et al., 2011). However, colorectal cancer cells expressing a 
mutant VASP construct not-phosphorylatable at Ser239 are resistant to GCC effects on 
VASP intracellular distribution and membrane protrusions (Zuzga et al., 2011). These 
findings are the most significant because they uncover the novel paradigm of a single 
intracellular biochemical reaction, VASP Ser239 phosphorylation, as an invasion 
suppressive mechanism for colon cancer (Zuzga et al., 2011). Hence, the loss of this 
mechanism during colorectal tumorigenesis, reflecting silencing of the GCC-cGMP-VASP 
system following hormonal deprivation (Birkenkamp-Demtroder et al., 2002; Cohen et al., 
1998; Notterman et al., 2001; Steinbrecher et al., 2000), may favour the acquisition of the 
metastatic cell morphology, characterized by dissolution of normal cell-matrix and cell-cell 
contacts, increased actin polymerization dynamics, and enhanced formation of membrane 
protrusions (Zuzga et al., 2011). 
4.2 Control of cancer cell dissemination 
Relocation of cancer cells to distant sites requires acquisition of novel motor abilities, 
enabling them to spread through remodelled matrix surfaces at both primary and secondary 
tissues. In primary tumors, cancer cell spreading in the direction of blood vessels initiates 
the migratory journey of the intravasation process (Fidler et al., 1978; Fidler, 2003). In 
secondary organs, tumor cell adhesion and spreading onto vascular endothelial surfaces 
starts cancer invasion of target parenchyma (Im et al., 2004; Wang et al., 2004). In this 
context, polarized cell spreading drives cancer cell migration in the direction of invasion by 
permitting the establishment of specialized cell-matrix contacts at membrane protrusions, 
which mediates actin cytoskeleton-driven anchorage and traction of the cell body (Small et 
al., 1996). Thus, regulators of the cytoskeleton, adhesion receptors and extracellular 
proteases, which universally control spreading and migration in cells, are key players 
underlying cancer dissemination (Yamaguchi & Condeelis, 2007). Since its signalling 
through cGMP and VASP controls actin cytoskeletal dynamics and membrane protrusions 
in colon cancer cells (Zuzga et al., 2011), the GCC pathway may exert substantial impacts on 
those processes underlying formation of distant metastasis. Consistent with this hypothesis, 
elimination of GCC signalling in mice accelerates cell migration along the intestinal crypt-
villus axis (Li et al., 2007a). Of relevance, basal GCC activity appears insufficient to 
restraining epithelial cell motility, as demonstrated by the increased migration of intestinal 
mucosa cells in mice with targeted ligand (guanylin) deletion (Steinbrecher et al., 2002). 
These observations suggest a model in which loss of hormone expression at the beginning of 
colorectal tumorigenesis (Birkenkamp-Demtroder et al., 2002; Cohen et al., 1998; Notterman 
et al., 2001; Steinbrecher et al., 2000) results in the acquisition of increased migratory abilities 
by transformed cells, driven by the accelerated formation of locomotory organelles 
mediating cell spreading and invasion (Zuzga et al., 2011). 
A significant regulator of colorectal cancer cell migration and dissemination is the MMP-9 
secreted by tumor epithelial cells (Lubbe et al., 2006). Beyond matrix degradation, this 
MMP-9 promotes the spreading and migration of colon cancer cells along two dimensional 
surfaces (Lubbe et al., 2006). Moreover, the catalytic activity of cancer cell MMP-9 is 
required for optimal colon tumor cell seeding of target mouse organs (Lubbe et al., 2006), an 
effect probably reflecting remodelling of the tumor pericellular microenvironment by MMP-
9 (Fridman et al., 2003). Accordingly, inhibitors of MMP-9 suppress the formation of 
colorectal liver metastasis in an animal model (Aparicio et al., 1999). The significance of 
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MMP-9 for colon cancer metastasis is further underscored by its universal role in regulating 
migration and invasion across different cell types (Buisson et al., 1996; Leppert et al., 1995; 
Sanceau et al., 2003; Schultz et al., 1988; Yu & Stamenkovic, 1999). Importantly, ligand-
dependent GCC signalling through cGMP suppresses the function of the MMP-9 produced 
by colorectal cancer cells (Lubbe et al., 2009). Activation of the GCC pathway suppresses 
tumor cell spreading, migration and dissemination by specifically inhibiting the secretion of 
cancer cell MMP-9 in the extracellular space (Lubbe et al., 2009). Further, colon tumor cells 
treated with GCC ligands fail to form metastatic colonies on mouse diaphragms following 
intraperitoneal injections (Lubbe et al., 2009). This effect also depends on the ability of GCC 
to inhibit cancer cell MMP-9, as demonstrated by the resistance of cells overexpressing 
MMP-9 to GCC-mediated inhibition of peritoneal metastasis (Lubbe et al., 2009). 
Conceivably, a silent GCC pathway in colorectal carcinogenesis (Birkenkamp-Demtroder et 
al., 2002; Cohen et al., 1998; Notterman et al., 2001; Steinbrecher et al., 2000) facilitates colon 
tumor invasion and metastatic dissemination by removing a key inhibitory mechanism 
restraining the oncogenic activity of cancer cell MMP-9. 
5. The GCC pathway as a source of novel clinical targets 
As discussed above, the loss of ligand-dependent GCC signalling produces a dormant 
GCC/cGMP pathway, which has significant impacts on the initiation, progression and 
metastasis of colorectal cancer. Conversely, deregulation of that pathway and its individual 
molecular components uncovers novel targets with unexploited clinical potential for 
improved diagnosis and therapy of patients. Thus, detection of hormone downregulation in 
colon biopsies could indicate presence of intestinal carcinogenesis and demand appropriate 
follow-up (Cohen et al., 1998; Notterman et al., 2001). The selective expression of GCC in 
colorectal tumor cells at metastatic sites (Carrithers et al., 1994, 1996; Waldman et al., 1998), 
suggests its utility as a diagnostic marker and specific target for delivering imaging and 
therapeutic agents in vivo (Gali et al., 2001; Wolfe et al., 2002). Indeed, clinical trials are 
confirming the value of GCC as a diagnostic marker for molecular staging of patients and 
prognostic indicator of colorectal cancer recurrence (Mejia et al., 2010; Waldman et al., 2009). 
Moreover, the structural preservation of GCC and its intracellular effectors offers the GCC 
hormone replacement therapy as a novel clinical paradigm for the prevention and treatment 
of colorectal cancer (Pitari et al., 2007). In this context, oral administration of uroguanylin 
prevents polyp formation in an animal model of intestinal tumorigenesis (Shailubhai et al., 
2000). Further, the resistance to colon cancer initiation and progression exhibited by 
populations living in the developing world (Pitari et al., 2003; Shailubhai et al., 2000), where 
enterotoxigenic infections are highest, suggests that replacement therapy with the 
exogenous GCC ligand ST, the enterotoxin produced by E. coli, might be an effective 
treatment for colorectal cancer patients (Pitari et al., 2007). This latter consideration is 
supported by observations that ST is the most potent GCC agonist available (Lucas et al., 
2000), and the only ligand successfully investigated to fully restore the tumor suppressor 
activities of the GCC pathway in colorectal cancer cells (Lubbe et al., 2009; Pitari et al., 2001, 
2003, 2005, 2007; Zuzga et al.,2011). 
Distal components of the GCC pathway also could be exploited in original clinical 
applications against colon cancer. As expected for its significance in intestinal mucosa 
homeostasis, the intracellular GCC signalome comprises a complex molecular network 
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(Pitari et al., 2007), probably still incomplete and in which each of the molecular elements 
may deserve critical translational evaluations. For some of these, preclinical testing is 
currently ongoing that is revealing emerging features as promising colorectal cancer bio-
targets (Table 1). One model is the CaR, whose surface expression in colon cancer cells is 
conditionally regulated by activation of GCC signalling (Pitari et al., 2008). The dormant 
GCC pathway probably contributes to the reduced CaR expression observed in colorectal 
tumors (Chakrabarty et al., 2003; Kallay et al., 2003), a mutational event with clinical 
potential as a diagnostic marker of disease progression (Pitari et al., 2008). Moreover, CaR 
activation by extracellular Ca2+ inhibits cell proliferation (Chakrabarty et al., 2003), and 
dietary Ca2+ supplementation has been proposed as a chemopreventive strategy for colon 
cancer (Cho et al., 2004). Since restoration of the GCC pathway with exogenous ST 
administration potentiates antitumorigenic CaR signalling in human colon carcinoma cells 
(Pitari et al., 2008), combinatorial therapies including dietary Ca2+ and GCC ligand 
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Table 1. Examples of emergent colon cancer molecular targets from the GCC pathway. 
Another intriguing effector of the GCC pathway is MMP-9, whose cancer cell 
compartmentalization depends on intracellular cGMP signalling (Lubbe et al., 2009). A silent 
GCC network may favour increased release and proteolytic activity of MMP-9 at the tumor 
pericellular space (Lubbe et al., 2009), thereby promoting matrix remodelling and invasion 
(Curran & Murray, 1999). Importantly, colon cancer cell MMP-9 behaves as a selective 
prognostic and predictive biomarker for disease stage stratification and therapeutic regimen 
selection in patients (Bendardaf et al., 2010; Zuzga et al., 2008). Reactivation of the GCC 
pathway with ST, in turn, is one successful strategy to specifically inhibit MMP-9 in tumor 
epithelial cells, without collateral damage in normal tissue, that has been suggested for the 
chemoprevention of colorectal cancer metastasis (Lubbe et al., 2009). Further, recent studies 
are indicating VASP as yet another GCC target with attractive translational applications for 
patients with colon cancer (Zuzga et al., 2011). VASP is a crucial actin-binding protein 
controlling membrane protrusion geometry, cell adhesion and migration (Bear et al., 2002; 
Krause et al., 2003; Mejillano et al., 2004). Dormancy of the GCC pathway in tumorigenesis 
depletes colon cancer cells of the cGMP-dependent VASP Ser phosho-species, molecular 
regulators of VASP activity at dynamic membrane regions (Krause et al., 2003). Thus, loss of 
VASP Ser phosphorylation may represent a novel prognostic biomarker of colon cancer 
www.intechopen.com
 
Emergent Concepts from the Intestinal Guanylyl Cyclase C Pathway 
 
273 
progression (Zuzga et al., 2011). Conversely, reconstitution of VASP Ser phosphorylation 
could be exploited as an original paradigm for the chemoprevention of cancer migration and 
invasion, because the potent GCC ligand ST suppresses the malignant cell morphology and 
its pathological functions in colon cancer (Zuzga et al., 2011). 
6. Conclusion 
A novel paradigm is emerging in which colorectal cancer, one of the top cancer killers in the 
world, is pathogenetically conditioned by a dormant GCC pathway, developed early in 
tumorigenesis following specific ligand downregulation. Indeed, GCC and its paracrine 
hormones restrict the proliferative crypt phenotype and promote the normal epithelial cell 
morphology by orchestrating an articulated intracellular network comprising 
interconnected, but functionally distinct molecular effectors. Silencing of the pathway for 
loss of agonist-induced GCC/cGMP signalling alters the activity of those molecules with 
profound consequences for the initiation and progression of colorectal transformation (Fig. 
1). Virtually all the key processes underlying carcinogenesis and metastasis are enhanced by 
dysregulation of the GCC pathway components, including proliferation, survival, genetic 
instability, migration, matrix remodelling and invasion. At the same time, the dormant 
pathway creates unexplored opportunities for novel diagnostic applications. This is because 
the biochemical deregulation that ensues from the silent cGMP-dependent machinery can be 
traced by analysis of the single pathway components at the molecular level. As a result, 
novel molecular fingerprints of colorectal carcinogenesis are emerging from the GCC 
pathway that can be exploited as clinical prognostic or predictive indicators of disease. 
Restoration of the lost function by the GCC pathway in colorectal tumors also is proving its 
great translational value. Preclinical studies indicate that, though dormant, the pathway is 
largely intact and can be reconstituted simply by ligand replacement. Thus, administration 
of bacterial enterotoxin STs, potent GCC agonists, suppresses proliferation, migration, 
matrix degradation, invasion and metastasis by colorectal cancer cells. Altogether, these 
findings support the notion that oral replacement therapy with GCC ligands could represent 
a novel strategy for both the chemoprevention and cure of colorectal cancer. Additional 
therapies targeting the individual pathway components, either alone or in combination, also 
are being developed with the goal to improve clinical efficacy and selectivity. However, 
information from clinical testing is still missing and important questions remain to be 
addressed before this knowledge could be applied to the patient bed. In particular, general 
gastrointestinal toxicity worries need to be dissipated as GCC ligands such as ST are known 
for their potent diarrheagenic effects. Also, the temporal profile of GCC-targeted therapy 
will require complete characterization, including estimation of duration of treatments and 
effects. Finally, pharmacokinetics evaluation will need to be performed to accurately define 
dosing and timing regimens. In summary, the intestinal GCC pathway is an exciting 
potential source of novel diagnostic and therapeutic targets that could significantly affect 
the clinical management and disease outcome of patients with colorectal cancer. 
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